Developer docs
API playgroundTry for free, no card

Search company profiles

Micrima

Full company profile

uuid00026ar

Namestring
Micrima
Legal namestring
Micrima Limited
Websiteurl
micrima.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Micrima Limited is a Bristol, UK-based medical technology company, founded in 2005, that has developed Mi~Scan, a CE-marked Class IIa handheld medical device that uses low-energy radio-frequency signals to measure breast tissue density without ionizing radiation or breast compression. A trained practitioner performs the scan in an approximate 10-minute in-person appointment, producing BI-RADS density categories and percentage density values for each breast; the device is validated for breast tissue thickness of 20-196 mm and is positioned as complementary to mammography, particularly for younger women and women with dense breast tissue where standard mammograms may be less informative. The company operates under EU MDR 2017/745 (Notified Body IMQ 0051) and holds ISO 13485 quality management certification from BSI. Its underlying technology is protected by nine granted patents.

The product portfolio combines hardware measurement with a regulated software stack. Mi~Score is an optional add-on service that integrates Mi~Scan density data with structured clinical inputs and applies Tyrer-Cuzick and BOADICEA breast cancer risk models — both recognized in NHS/NICE familial-risk pathways — to generate personalized risk estimates, visual density maps, and longitudinal trend tracking. Outputs are delivered through Mi~Scan+, a CE-marked Class I software medical device accessed via web portal. Pivotal clinical validation was conducted with Leeds Teaching Hospitals NHS Trust (approximately 1,000 women), and community acceptability was assessed in a study sponsored by NHS Greater Manchester Cancer Alliance.

Micrima operates a direct-to-consumer service model. Customers request information via the website, receive personal outreach from the Partnerships & Growth Manager (Imogen), and book in-person appointments at Micrima HQ (Two Glass Wharf, Bristol) or selected partner locations around the UK. Pricing is quote-based and not publicly disclosed; payment is accepted via Visa, Mastercard, American Express, Apple Pay, PayPal, and Klarna. Revenue derives from per-appointment Mi~Scan scans and optional Mi~Score professional-services reports. The customer base consists of individual consumers — general-population women, women with family history of breast cancer, and women with dense breasts — rather than enterprise B2B contracts. Total disclosed funding across eight rounds from 2006 through April 2021 is approximately $23.3M, with investors including Technology Venture Partners, ACF Investors, Nesta Ventures, Swarraton Partners, YFM Equity Partners, Parkwalk Advisors, Renaissance Capital Partners, VentureFounders, the University of Bristol Enterprise Fund, Quester Capital, and Sulis Innovation. No operating geographies beyond the United Kingdom are disclosed.

Short descriptiontext

Micrima Limited is a UK medical device company that operates the CE-marked Mi~Scan handheld radio-frequency breast density measurement service, serving adult women seeking radiation-free, compression-free breast density information and personalized cancer risk profiling via direct-to-consumer in-person appointments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBristol, United Kingdom
HQ citystring
Bristol
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breast density measurement, radiation-free imaging, radio-frequency diagnostics, breast cancer screening, women's health imaging
Industry2 codes
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAFAJAJ
Women’s Imaging & Breast Health Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Diagnostic Imaging Centers621512
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Breast Imaging Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Mi~Scan Appointment Service
TypeOne Time License
Description

In-person scan service where trained practitioners perform breast density measurements using the Mi~Scan handheld device. Customers book appointments through the website booking system and pay for the service at point of sale. Payment accepted via Visa, Mastercard, American Express, Apple Pay, PayPal, and Klarna.

micrima.com
2Mi~Score Optional Add-on Report
TypeProfessional Services
Description

Optional supplemental service that builds on Mi~Scan measurements, providing density maps, personalized breast cancer risk estimates using validated clinical models (Tyrer-Cuzick, BOADICEA), and longitudinal tracking. Delivered through Mi~Scan+ web portal (Class I software medical device).

micrima.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Technology or R&D
Pricing details1 tier
1Quote-based pricing - not publicly disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing information provided upon request through information pack. No pricing tiers or amounts mentioned on website.

micrima.com
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 3 records shown
1Mi~Scan®
Description

Radiation-free breast density measurement device using radio-frequency technology. CE-marked Class IIa medical device that measures breast tissue properties to provide personal breast-density information.

micrima.com
+2 more records
Core offering1 text field

Micrima sells in-person breast density measurement appointments through its proprietary Mi~Scan® handheld device, which uses low-energy radio-frequency signals (no radiation, no compression) to give women personal breast-density information. The optional Mi~Score® add-on layers Tyrer-Cuzick and BOADICEA-validated personalised breast cancer risk profiling, density maps and longitudinal tracking delivered via the Mi~Scan®+ Class I software web portal.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • ~1,000 women participated in pivotal clinical investigation at Leeds Teaching Hospitals NHS Trust
+1 more record
Product overview1 text field

Micrima offers a unified breast health monitoring system built around the Mi~Scan® handheld radio-frequency device for measuring breast density. This core device connects to the Mi~Scan®+ Web Portal, a regulated Class I software medical device that processes measurements into the optional Mi~Score® service — providing visual density maps and personalised breast cancer risk estimates using established clinical risk models. The architecture combines hardware measurement with cloud-based software analysis for comprehensive breast density assessment.

Product and service3 records
1Mi~Scan® breast density scan service
CategoryBreast density measurement service
Description

An in-person appointment in which a trained practitioner uses the handheld Mi~Scan® device to take a series of gentle radio-frequency measurements of the breast, providing personal breast-density information (BI-RADS category and percentage density for each breast) in approximately 10 minutes, with no radiation and no compression. Targeted at adult women seeking personal breast-density information, including those with dense breasts and family history of breast cancer.

2Mi~Score® personal breast cancer risk profiling
CategoryPersonalised breast cancer risk profiling
Description

An optional add-on service that combines Mi~Scan® breast-density data with personal/family history, lifestyle and genetic profile inputs and applies Tyrer-Cuzick and BOADICEA validated risk models to generate personalised breast cancer risk estimates, visual density maps and trend tracking over time. Delivered to the customer through the Mi~Scan®+ Web Portal.

3Mi~Scan®+ Web Portal (Class I software medical device)
CategorySoftware medical device (patient reporting portal)
Description

A regulated Class I software medical device web portal that delivers Mi~Score® outputs to customers, including breast cancer statistical risk prediction percentages, graphical visualisation of estimated fibroglandular tissue distribution, percentage-based density measurements and longitudinal density history.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical validation partner for pivotal investigation of Mi~Scan technology. Approximately 1,000 women participated in clinical study validating the device's safety and performance. Mi~Scan is clinically validated with Leeds Teaching Hospitals NHS Trust.

2NHS Greater Manchester Cancer Alliance
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sponsored community acceptability study assessing Mi~Scan use in everyday settings. Demonstrated exceptionally high acceptance rates among participants. Study supports use in community-based settings.

micrima.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Volpara builds software that quantifies breast density from mammograms and provides personalised breast cancer risk scoring. It is the closest direct peer to Micrima's Mi~Score offering, both addressing objective breast density and risk assessment, although Volpara is software-only and rides on incumbent mammography hardware.

TypeDirect peer
Description

iCAD offers AI-powered breast health solutions including density assessment and cancer detection, competing with Mi~Score on risk profiling. Both companies target the breast density / risk stratification workflow for clinicians and patients.

TypeDirect peer
Description

Densitas provides AI-based breast density measurement and risk assessment software integrated with mammography workflows. It is an emerging direct competitor in the density-assessment category that Micrima addresses via Mi~Scan/Mi~Score.

TypeBroad incumbent
Description

Hologic is the dominant mammography hardware and breast health incumbent, whose installed base underpins much of the breast-imaging market. While not offering an RF density device, Hologic's breast health portfolio (including its own density-assessment software) is the established alternative Micrima competes against in clinical settings.

TypeBroad incumbent
Description

GE HealthCare provides mammography systems and broader breast imaging solutions to hospitals and screening programmes worldwide. As a major imaging incumbent, it sets the clinical workflow standard that novel entrants like Micrima must integrate with or differentiate from.

TypeBroad incumbent
Description

Siemens Healthineers offers mammography and breast imaging equipment, including AI-enabled density and risk assessment tools. It is a broad incumbent competitor in the breast imaging category where Micrima is positioning a complementary RF-based density service.

TypeEmerging player
Description

Lunit develops AI solutions for cancer detection and tissue characterisation, including breast density and risk assessment. As an emerging AI player, it competes in the same risk-stratification layer as Micrima's Mi~Score, but does so via algorithms layered on mammograms rather than a dedicated RF hardware device.

TypeEmerging player
Description

ScreenPoint Medical provides AI-based breast imaging decision support, including density and cancer detection tools for mammography. It overlaps with Micrima's Mi~Score risk-profiling proposition by addressing personalised breast assessment within existing clinical imaging workflows.

9Therapy Analytics / Myriad Genetics (risk-model providers)
TypeOthers
Description

Myriad Genetics offers hereditary cancer risk testing (including BRCA1/BRCA2 used in Mi~Score inputs) and is a supplier of genetic data feeding the same breast cancer risk-assessment workflow Micrima commercialises. Relevant as an ecosystem enabler and partial competitor for risk-stratified breast health consumers.

10Prevent Breast Cancer (charity / clinical research partner)
TypeOthers
Description

UK-based charity funding breast cancer prediction, prevention, and early-detection research. Comparable as a UK stakeholder in the dense-breast awareness and risk-assessment space that Micrima's Mi~Scan / Mi~Score proposition targets, and a potential partnership channel rather than a direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Micrima

Breast Imaging Diagnosticsmicrima.com

Micrima Limited is a UK medical device company that operates the CE-marked Mi~Scan handheld radio-frequency breast density measurement service, serving adult women seeking radiation-free, compression-free breast density information and personalized cancer risk profiling via direct-to-consumer in-person appointments.

What Micrima does

Micrima Limited is a Bristol, UK-based medical technology company, founded in 2005, that has developed Mi~Scan, a CE-marked Class IIa handheld medical device that uses low-energy radio-frequency signals to measure breast tissue density without ionizing radiation or breast compression. A trained practitioner performs the scan in an approximate 10-minute in-person appointment, producing BI-RADS density categories and percentage density values for each breast; the device is validated for breast tissue thickness of 20-196 mm and is positioned as complementary to mammography, particularly for younger women and women with dense breast tissue where standard mammograms may be less informative. The company operates under EU MDR 2017/745 (Notified Body IMQ 0051) and holds ISO 13485 quality management certification from BSI. Its underlying technology is protected by nine granted patents.

The product portfolio combines hardware measurement with a regulated software stack. Mi~Score is an optional add-on service that integrates Mi~Scan density data with structured clinical inputs and applies Tyrer-Cuzick and BOADICEA breast cancer risk models — both recognized in NHS/NICE familial-risk pathways — to generate personalized risk estimates, visual density maps, and longitudinal trend tracking. Outputs are delivered through Mi~Scan+, a CE-marked Class I software medical device accessed via web portal. Pivotal clinical validation was conducted with Leeds Teaching Hospitals NHS Trust (approximately 1,000 women), and community acceptability was assessed in a study sponsored by NHS Greater Manchester Cancer Alliance.

Micrima operates a direct-to-consumer service model. Customers request information via the website, receive personal outreach from the Partnerships & Growth Manager (Imogen), and book in-person appointments at Micrima HQ (Two Glass Wharf, Bristol) or selected partner locations around the UK. Pricing is quote-based and not publicly disclosed; payment is accepted via Visa, Mastercard, American Express, Apple Pay, PayPal, and Klarna. Revenue derives from per-appointment Mi~Scan scans and optional Mi~Score professional-services reports. The customer base consists of individual consumers — general-population women, women with family history of breast cancer, and women with dense breasts — rather than enterprise B2B contracts. Total disclosed funding across eight rounds from 2006 through April 2021 is approximately $23.3M, with investors including Technology Venture Partners, ACF Investors, Nesta Ventures, Swarraton Partners, YFM Equity Partners, Parkwalk Advisors, Renaissance Capital Partners, VentureFounders, the University of Bristol Enterprise Fund, Quester Capital, and Sulis Innovation. No operating geographies beyond the United Kingdom are disclosed.

Micrima firmographics

Firmographics
Name
Micrima
Legal name
Micrima Limited
Website
https://micrima.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Micrima Limited is a UK medical device company that operates the CE-marked Mi~Scan handheld radio-frequency breast density measurement service, serving adult women seeking radiation-free, compression-free breast density information and personalized cancer risk profiling via direct-to-consumer in-person appointments.
Ownership category
akta.pro rank

Micrima industry classification

Industry
Product category
Breast Imaging Diagnostics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Diagnostic Imaging Centers (621512)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAFAJAJ
Women’s Imaging & Breast Health Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers

Keywords

  • Breast density measurement
  • Radiation-free imaging
  • Radio-frequency diagnostics
  • Breast cancer screening
  • Women's health imaging

Where Micrima is headquartered

Location

Headquarters

HQ city
Bristol
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Micrima business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D

Revenue model

  1. Mi~Scan Appointment Service: In-person scan service where trained practitioners perform breast density measurements using the Mi~Scan handheld device. Customers book appointments through the website booking system and pay for the service at point of sale. Payment accepted via Visa, Mastercard, American Express, Apple Pay, PayPal, and Klarna.
  2. Mi~Score Optional Add-on Report: Optional supplemental service that builds on Mi~Scan measurements, providing density maps, personalized breast cancer risk estimates using validated clinical models (Tyrer-Cuzick, BOADICEA), and longitudinal tracking. Delivered through Mi~Scan+ web portal (Class I software medical device).

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing - not publicly disclosed

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Micrima product offering

Product offering

Core offering

Micrima sells in-person breast density measurement appointments through its proprietary Mi~Scan® handheld device, which uses low-energy radio-frequency signals (no radiation, no compression) to give women personal breast-density information. The optional Mi~Score® add-on layers Tyrer-Cuzick and BOADICEA-validated personalised breast cancer risk profiling, density maps and longitudinal tracking delivered via the Mi~Scan®+ Class I software web portal.

Product overview

Micrima offers a unified breast health monitoring system built around the Mi~Scan® handheld radio-frequency device for measuring breast density. This core device connects to the Mi~Scan®+ Web Portal, a regulated Class I software medical device that processes measurements into the optional Mi~Score® service — providing visual density maps and personalised breast cancer risk estimates using established clinical risk models. The architecture combines hardware measurement with cloud-based software analysis for comprehensive breast density assessment.

Differentiator

Problem solved

Functional benefit

Brands

  • Mi~Scan®: Radiation-free breast density measurement device using radio-frequency technology. CE-marked Class IIa medical device that measures breast tissue properties to provide personal breast-density information.
  • Mi~Score®
  • Mi~Scan®+

Products and services

  • Mi~Scan® breast density scan service An in-person appointment in which a trained practitioner uses the handheld Mi~Scan® device to take a series of gentle radio-frequency measurements of the breast, providing personal breast-density information (BI-RADS category and percentage density for each breast) in approximately 10 minutes, with no radiation and no compression. Targeted at adult women seeking personal breast-density information, including those with dense breasts and family history of breast cancer.
  • Mi~Score® personal breast cancer risk profiling An optional add-on service that combines Mi~Scan® breast-density data with personal/family history, lifestyle and genetic profile inputs and applies Tyrer-Cuzick and BOADICEA validated risk models to generate personalised breast cancer risk estimates, visual density maps and trend tracking over time. Delivered to the customer through the Mi~Scan®+ Web Portal.
  • Mi~Scan®+ Web Portal (Class I software medical device) A regulated Class I software medical device web portal that delivers Mi~Score® outputs to customers, including breast cancer statistical risk prediction percentages, graphical visualisation of estimated fibroglandular tissue distribution, percentage-based density measurements and longitudinal density history.

Quantifiable outcome

  • ~1,000 women participated in pivotal clinical investigation at Leeds Teaching Hospitals NHS Trust
  • +1 more outcomes

Companies that use Micrima

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Micrima technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature3 records

Micrima partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Leeds Teaching Hospitals NHS TrustcoreStrategic or Co-development PartnerClinical validation partner for pivotal investigation of Mi~Scan technology. Approximately 1,000 women participated in clinical study validating the device's safety and performance. Mi~Scan is clinically validated with Leeds Teaching Hospitals NHS Trust.
  • NHS Greater Manchester Cancer AlliancecoreStrategic or Co-development PartnerSponsored community acceptability study assessing Mi~Scan use in everyday settings. Demonstrated exceptionally high acceptance rates among participants. Study supports use in community-based settings.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Micrima competitors and assessment

Company assessment

Direct peers

  • Volpara Health: Volpara builds software that quantifies breast density from mammograms and provides personalised breast cancer risk scoring. It is the closest direct peer to Micrima's Mi~Score offering, both addressing objective breast density and risk assessment, although Volpara is software-only and rides on incumbent mammography hardware.
  • iCAD: iCAD offers AI-powered breast health solutions including density assessment and cancer detection, competing with Mi~Score on risk profiling. Both companies target the breast density / risk stratification workflow for clinicians and patients.
  • Densitas: Densitas provides AI-based breast density measurement and risk assessment software integrated with mammography workflows. It is an emerging direct competitor in the density-assessment category that Micrima addresses via Mi~Scan/Mi~Score.

Broad incumbents

  • Hologic: Hologic is the dominant mammography hardware and breast health incumbent, whose installed base underpins much of the breast-imaging market. While not offering an RF density device, Hologic's breast health portfolio (including its own density-assessment software) is the established alternative Micrima competes against in clinical settings.
  • GE HealthCare: GE HealthCare provides mammography systems and broader breast imaging solutions to hospitals and screening programmes worldwide. As a major imaging incumbent, it sets the clinical workflow standard that novel entrants like Micrima must integrate with or differentiate from.
  • Siemens Healthineers: Siemens Healthineers offers mammography and breast imaging equipment, including AI-enabled density and risk assessment tools. It is a broad incumbent competitor in the breast imaging category where Micrima is positioning a complementary RF-based density service.

Emerging players

  • Lunit: Lunit develops AI solutions for cancer detection and tissue characterisation, including breast density and risk assessment. As an emerging AI player, it competes in the same risk-stratification layer as Micrima's Mi~Score, but does so via algorithms layered on mammograms rather than a dedicated RF hardware device.
  • ScreenPoint Medical: ScreenPoint Medical provides AI-based breast imaging decision support, including density and cancer detection tools for mammography. It overlaps with Micrima's Mi~Score risk-profiling proposition by addressing personalised breast assessment within existing clinical imaging workflows.

Others

  • Therapy Analytics / Myriad Genetics (risk-model providers): Myriad Genetics offers hereditary cancer risk testing (including BRCA1/BRCA2 used in Mi~Score inputs) and is a supplier of genetic data feeding the same breast cancer risk-assessment workflow Micrima commercialises. Relevant as an ecosystem enabler and partial competitor for risk-stratified breast health consumers.
  • Prevent Breast Cancer (charity / clinical research partner): UK-based charity funding breast cancer prediction, prevention, and early-detection research. Comparable as a UK stakeholder in the dense-breast awareness and risk-assessment space that Micrima's Mi~Scan / Mi~Score proposition targets, and a potential partnership channel rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Micrima social profiles

Digital presence

Micrima compliance and trust

Trust signal

Compliance4 records

Micrima financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Micrima leadership team

Management profile

Number of profiles

Profiles6 records

Micrima funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Micrima M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micrima

What does Micrima do?

Micrima sells in-person breast density measurement appointments through its proprietary Mi~Scan® handheld device, which uses low-energy radio-frequency signals (no radiation, no compression) to give women personal breast-density information. The optional Mi~Score® add-on layers Tyrer-Cuzick and BOADICEA-validated personalised breast cancer risk profiling, density maps and longitudinal tracking delivered via the Mi~Scan®+ Class I software web portal.

Is Micrima a public or private company?

Micrima is a private company. It is classified as venture growth investor backed and is currently operating.

When was Micrima founded?

Micrima was founded in 2005. It employs 51 to 100 people.

Where is Micrima based?

Micrima is headquartered in Bristol, United Kingdom, in the Europe region.

How does Micrima make money?

Two revenue lines are on record. Mi~Scan Appointment Service is the primary driver. The others are mi~Score Optional Add-on Report.

Who are Micrima's main competitors?

Direct peers on record are Volpara Health, iCAD and Densitas. Broad incumbents are Hologic, GE HealthCare and Siemens Healthineers. Emerging players are Lunit and ScreenPoint Medical. Others are Therapy Analytics / Myriad Genetics (risk-model providers) and Prevent Breast Cancer (charity / clinical research partner).

Does Micrima have an API?

No public API is recorded for Micrima.

What industry is Micrima in?

Micrima's product category is Breast Imaging Diagnostics. Its primary akta.pro industry code is HLAHABAF, Mammography & Breast Imaging Systems, with a secondary code of HLAFAJAJ, Women’s Imaging & Breast Health Centers. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TechRound5 Startups Crowdfunding w/c 24.08.2026A weekly roundup of UK startups seeking crowdfunding funding, with five companies listed. Micrima, HONEY & GREENS and RT Bio Systems are on Crowdcube, while Distinctive Minds Clinical and Veyro are on Crowdfunder. Funding amounts were disclosed for RT Bio Systems (£15,000), Distinctive Minds Clinical (£2,000) and Veyro (£10,000), with no amounts given for Micrima or HONEY & GREENS.BusinessCloudStart-up raises £4.4m for breast cancer screening techMicrima, a Bristol-based start-up, raised £4.4 million in additional equity funding, bringing total funding to £10.7 million. The capital will support the full commercial launch of its MARIA breast cancer screening system later in 2018. The system uses harmless radio waves and has been trialled in over 400 UK women.UKTNMicrima bags £4.4m to continue developing breast screening techMicrima raised an additional £4.4m in equity funding led by Technology Venture Partners, The Angel CoFund and Venture Founders, bringing total funding to £10.7m. The funds will develop its radiowave breast imaging system, with a full commercial launch planned later this year.FinSMEsMicrima Raises Additional £4.4M in Equity FundingMicrima, a Bristol-based breast imaging company, raised £4.4m in equity funding led by Technology Venture Partners, The Angel CoFund, and Venture Founders. The round brings total funding to £10.7m, to be used for developing its CE Marked radiowave breast imaging system, MARIA, and expanding the team. The company plans a full commercial launch later in 2018.CrowdFund InsiderMicrima Closes £2.6 Million Funding Round with Participation from VentureFoundersMicrima, a Bristol-based med-tech firm, closed a £2.6 million funding round with VentureFounders, with half from new high-net-worth individuals. The company's MARIA radio-wave breast imaging system, approved in 2015, is expected to enter commercial use before year-end. A next version with enhanced functionality is due early next year.MedCity NewsImaging startup garners $3.45 million to detect breast cancer earlyMicrima raised $3.45 million to commercialize its CE-Marked radiowave breast imaging system. The non-ionizing technology avoids breast compression and takes about five minutes, compared to 10-15 minutes for mammography. It is being evaluated in a clinical trial for women under 40.FinSMEsMicrima Raises £2.6M in FundingMicrima, a Bristol-based breast imaging company, closed a £2.6M funding round with backers including Technology Venture Partners, Swarraton Partners, and the University of Bristol Enterprise Fund. The funds will accelerate development and start commercialization by end of year, with a second MARIA system release early next year.FinSMEsMicrima Raises £600K in FundingMicrima, a Bristol-based breast cancer imaging company, raised £600k from angel investors and government-backed funding. The company will use the proceeds to improve its imaging system, collect clinical data at Southmead Hospital, and hire for product development and regulatory approval.